Epigenomics
Market Cap
€15.3m
Last Updated
2021/08/01 17:47 UTC
Data Sources
Company Financials +
Executive Summary
Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 13.2% per year for the next 3 years
Shareholders have been substantially diluted in the past year
+ 3 more risks
Snowflake Analysis
Adequate balance sheet with limited growth.
Share Price & News
How has Epigenomics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ECX is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ECX's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of German stocks.
Market Performance
7 Day Return
3.2%
ECX
-5.9%
DE Biotechs
-0.6%
DE Market
1 Year Return
-93.7%
ECX
-23.7%
DE Biotechs
29.3%
DE Market
Return vs Industry: ECX underperformed the German Biotechs industry which returned -23.7% over the past year.
Return vs Market: ECX underperformed the German Market which returned 29.3% over the past year.
Shareholder returns
| ECX | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.2% | -5.9% | -0.6% |
| 30 Day | 5.4% | -12.0% | -0.2% |
| 90 Day | 3.8% | -17.1% | 2.2% |
| 1 Year | -93.7%-93.7% | -23.5%-23.7% | 33.4%29.3% |
| 3 Year | -92.0%-92.8% | -29.9%-30.5% | 29.3%18.5% |
| 5 Year | -96.0%-96.4% | 37.0%33.9% | 53.9%32.7% |
Long-Term Price Volatility Vs. Market
How volatile is Epigenomics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
We're Keeping An Eye On Epigenomics' (ETR:ECX) Cash Burn Rate5 months ago | Simply Wall St
When Will Epigenomics AG (ETR:ECX) Breakeven?Valuation
Is Epigenomics undervalued compared to its fair value and its price relative to the market?
1.18x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ECX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ECX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ECX is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: ECX is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ECX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ECX is good value based on its PB Ratio (1.2x) compared to the DE Biotechs industry average (2.7x).
Future Growth
How is Epigenomics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
-13.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ECX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ECX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ECX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ECX's revenue (67.2% per year) is forecast to grow faster than the German market (5.9% per year).
High Growth Revenue: ECX's revenue (67.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ECX's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Epigenomics performed over the past 5 years?
-8.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ECX is currently unprofitable.
Growing Profit Margin: ECX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ECX is unprofitable, and losses have increased over the past 5 years at a rate of 8.6% per year.
Accelerating Growth: Unable to compare ECX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ECX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.8%).
Return on Equity
High ROE: ECX has a negative Return on Equity (-152.88%), as it is currently unprofitable.
Financial Health
How is Epigenomics's financial position?
Financial Position Analysis
Short Term Liabilities: ECX's short term assets (€8.4M) exceed its short term liabilities (€2.5M).
Long Term Liabilities: ECX's short term assets (€8.4M) exceed its long term liabilities (€474.0K).
Debt to Equity History and Analysis
Debt Level: ECX is debt free.
Reducing Debt: ECX has no debt compared to 5 years ago when its debt to equity ratio was 12.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ECX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ECX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 2.9% each year
Dividend
What is Epigenomics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ECX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ECX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ECX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ECX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ECX's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.3yrs
Average management tenure
CEO
Greg Hamilton (51 yo)
5yrs
Tenure
€806,117
Compensation
Mr. Gregory Hamilton, also known as Greg, has been the Chief Executive Officer and Member of Executive Board at Epigenomics AG since July 1, 2016. Mr. Hamilton has over 20 years of management experience in...
CEO Compensation Analysis
Compensation vs Market: Greg's total compensation ($USD956.25K) is above average for companies of similar size in the German market ($USD485.77K).
Compensation vs Earnings: Greg's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: ECX's management team is considered experienced (4.3 years average tenure).
Board Members
Experienced Board: ECX's board of directors are considered experienced (5.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 100.7%.
Top Shareholders
Company Information
Epigenomics AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Epigenomics AG
- Ticker: ECX
- Exchange: XTRA
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €15.323m
- Shares outstanding: 11.82m
- Website: https://www.epigenomics.com
Number of Employees
Location
- Epigenomics AG
- Geneststrasse 5
- Berlin
- Berlin
- 10829
- Germany
Listings
Biography
Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal ca...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/08/01 17:47 |
| End of Day Share Price | 2021/07/30 00:00 |
| Earnings | 2021/03/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.